Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
PLx Pharma Winddown Corp. (PLXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
07/21/2023 8-K Quarterly results
07/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to Amended and Restated Bylaws of the Company"
05/26/2023 8-K Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, A...
Docs: "Certificate of Amendment of Certificate of Incorporation of PLx Pharma Inc",
"AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT DATED MAY 26, 2023"
04/13/2023 8-K Quarterly results
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/13/2023 8-K Quarterly results
01/20/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
08/12/2022 8-K Quarterly results
Docs: "PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update"
05/13/2022 8-K Quarterly results
04/21/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Corporation”), pursuant to the provisions of Section 109 of the Delaware General Corporation Law , hereby adopts these Amended and Restated Bylaws (the “Bylaws"
03/15/2022 8-K Investor presentation
03/11/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update MOMENTUM BUILDING FOR NOVEL VAZALORE LIQUID-FILLED ASPIRIN CAPSULES"
11/12/2021 8-K Quarterly results
Docs: "PLx Pharma Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, 2021 December 31, 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 82,554,297 $ 22,448,651 Accounts receivable, net 3,253,312 - Inventory 2,190,350 143,380 Prepaid expenses and other current assets 616,249 393,470 TOTAL CURRENT ASSETS 88,614,208 22,985,501 NON-CURRENT ASSETS Property and equipment, net 888,658 1,225,879 Right of use assets 255,121 327,161 Goodwill 2,061,022 2,061,022 Security deposit 17,036 17,036 TOTAL ASSETS $ 91,836,045 $ 26,616,599 LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 6,452,172 $ 862,568 Accrued bonuses 839,701 1,184,823 Accrued interest - 597,411 Term loan, net of discount and fees -..."
09/21/2021 8-K Investor presentation
08/06/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/14/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/30/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
11/16/2020 8-K Quarterly results
Docs: "The approval of an advisory vote on the frequency of the advisory vote on the compensation of our named executive officers; and",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"PLx Pharma Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2020 2019 ASSETS CURRENT ASSETS Cash and cash equivalents $ 9,086,525 $ 14,001,304 Accounts receivable — 18,683 Inventory, net 143,380 — Prepaid expenses and other current assets 387,801 263,268 TOTAL CURRENT ASSETS 9,617,706 14,283,255 NON-CURRENT ASSETS Property and equipment, net 1,252,434 1,466,646 Right of use assets 402,640 618,158 Goodwill 2,061,022 2,061,022 Security deposit 17,035 73,665 TOTAL ASSETS $ 13,350,837 $ 18,502,746 LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 612,367 $ 928,921 Accrued bonuses 718,092 1,166,821 Accrued interest 589,840 34,964 Current portion of term loan, net of discount...",
"PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration -- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 – Sparta, New Jersey, November 16, 2020 — PLx Pharma Inc. , a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, announced today that two chemistry and manufacturing control supplemental New Drug Applications , one for VAZALORE 325 mg and one for VAZALORE 81 mg dose , were submitted to the U.S. Food and Drug Administration in October for regulatory approval. The 325 mg sNDA provided information on..."
10/30/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
09/22/2020 8-K Quarterly results
08/14/2020 8-K Quarterly results
05/18/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of the Company",
"PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing SPARTA, N.J., May 18, 2020 — PLx Pharma Inc. , a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg , announced that at its special meeting of stockholders, held May 15, 2020, the stockholders approved the issuance of more than 20% of the Company’ s common stock pursuant to a private placement transaction with certain accredited investors and a change of control for purposes of NASDAQ Listing Rule 5635. Upon this stockholder approval, on May 15, 2020, the Company completed the $8 million convertible preferre..."
05/15/2020 8-K Quarterly results
Docs: "Sparta, New Jersey, May 15, 2020 — PLx Pharma Inc. , a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg , announced today certain financial and operational results for the three months ended March 31, 2020. Highlights of, and certain events subsequent to, the first quarter of 2020 include:"
05/04/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy